GLP-1 receptor agonist Archives

Eli Lilly and Company’s Foundayo approval could widen the obesity market faster than rivals expected

By Pallavi Madhiraju on April 3, 2026 Pharma & Biotech

Eli Lilly and Company’s Foundayo approval could reshape obesity treatment. Read what the oral GLP-1 launch changes for clinicians, payers, and rivals.

Sciwind Biosciences and Pfizer China bet on ecnoglutide as China’s GLP-1 market enters its most competitive phase

By Pallavi Madhiraju on February 28, 2026 Pharma & Biotech

Sciwind Biosciences partners with Pfizer China on ecnoglutide. Explore what this GLP-1 deal changes for obesity, diabetes, and China’s drug market.

Is oral GLP-1 finally viable? Inside Ascletis Pharma’s U.S. trial for ASC30

By Pallavi Madhiraju on January 26, 2026 Pharma & Biotech

Ascletis starts U.S. Phase II trial of ASC30 in type 2 diabetes. Find out what this oral GLP-1R agonist could mean for the future of metabolic therapies.

Can higher-dose Wegovy reshape the obesity treatment curve for Novo Nordisk?

By Venkatesh B on November 26, 2025 Pharma & Biotech

Novo Nordisk’s semaglutide 7.2 mg dose aims to raise Wegovy’s weight loss impact. Learn how this could shift obesity treatment and reshape clinical norms.